デフォルト表紙
市場調査レポート
商品コード
995401

勃起不全薬市場調査レポート:薬剤別(アバナフィル、ミューズ坐剤、シルデナフィル、タダラフィル、およびバルデナフィル)、投与方法別、エンドユーザー別-2026年までの予測-COVID-19の累積的影響

Erectile Dysfunction Drugs Market Research Report by Drug (Avanafil, Muse Suppository, and Sildenafil ), by Mode of Administration, by End-User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
勃起不全薬市場調査レポート:薬剤別(アバナフィル、ミューズ坐剤、シルデナフィル、タダラフィル、およびバルデナフィル)、投与方法別、エンドユーザー別-2026年までの予測-COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の勃起不全薬の市場規模は、2020年の19億6,840万米ドルから、2025年末までに26億8,261万米ドルに拡大すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。

当レポートでは、勃起不全薬市場について調査し、市場の概要とともに、薬剤別、投与方法別、エンドユーザー別、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 薬剤別見通し
  • 投与方法別見通し
  • エンドユーザー別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 世界の勃起不全薬市場、薬剤別

  • アバナフィル(ステンドラ)
  • ミューズ坐剤(アルプロスタジル)
  • シルデナフィル(バイアグラ)
  • タダラフィル(シアリス)
  • バルデナフィル(レビトラ、スタキシン)

第7章 世界の勃起不全薬市場、投与方法別

  • 注射
  • 経口
  • 局所

第8章 世界の勃起不全薬市場、エンドユーザー別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 南北アメリカの勃起不全薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の勃起不全薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第11章 欧州、中東・アフリカの勃起不全薬市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第13章 企業のユーザビリティプロファイル

  • Apricus Biosciences Inc.
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Cipla Ltd
  • Cristalia Produtos Quimicos Farmaceuticos Ltd.
  • Dong-A Pharmaceutical Co. Ltd.
  • Dr. Reddys Laboratories Ltd
  • Eli Lilly and Company
  • Endo International PLC
  • Ferring Pharmaceuticals
  • Futura Medical PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc
  • Meda Pharmaceuticals, Inc.
  • Metuchen Pharmaceuticals LLC
  • Mylan N.V.
  • Novartis International AG
  • Pfizer, Inc.
  • Promedon HQ
  • S.K. Chemicals Co. Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Vivus, Inc.

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2026
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), 2018-2026 (USD MILLION)
  • FIGURE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2020 VS 2026 (%)
  • FIGURE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2026
  • FIGURE 24. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, 2018-2026 (USD MILLION)
  • FIGURE 29. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2020 VS 2026 (%)
  • FIGURE 31. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2020 VS 2026 (USD MILLION)
  • FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2026
  • FIGURE 33. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2026 (USD MILLION)
  • FIGURE 38. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 40. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 42. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. CALIFORNIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. FLORIDA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. ILLINOIS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. NEW YORK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. OHIO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. PENNSYLVANIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. TEXAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 55. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 57. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 66. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 67. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 68. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 78. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 80. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 81. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 82. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CALIFORNIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. CALIFORNIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. CALIFORNIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. FLORIDA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. FLORIDA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. FLORIDA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. ILLINOIS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. ILLINOIS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. ILLINOIS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. NEW YORK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. NEW YORK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. NEW YORK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. OHIO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. OHIO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. OHIO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. PENNSYLVANIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. PENNSYLVANIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. PENNSYLVANIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. TEXAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. TEXAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. TEXAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 123. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: SCORES
  • TABLE 124. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BUSINESS STRATEGY
  • TABLE 125. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: PRODUCT SATISFACTION
  • TABLE 126. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: RANKING
  • TABLE 127. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 128. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 129. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: MERGER & ACQUISITION
  • TABLE 130. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 131. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 132. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: INVESTMENT & FUNDING
  • TABLE 133. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 134. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: LICENSE & PRICING
  • TABLE 135. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: CONTACT DETAILS
目次
Product Code: MRR-4348D129FAF5

The Global Erectile Dysfunction Drugs Market size was estimated at USD 1,968.40 Million in 2020 and expected to reach USD 2,103.97 Million in 2021, at a Compound Annual Growth Rate (CAGR) 7.22% to reach USD 2,991.58 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Erectile Dysfunction Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the Erectile Dysfunction Drugs Market was studied across Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra), Tadalafil (Cialis), and Vardenafil (Levitra, Staxyn).

Based on Mode of Administration, the Erectile Dysfunction Drugs Market was studied across Injections, Oral, and Topical.

Based on End-User, the Erectile Dysfunction Drugs Market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Geography, the Erectile Dysfunction Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Erectile Dysfunction Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Erectile Dysfunction Drugs Market, including Apricus Biosciences Inc., Aurobindo Pharma Ltd, Bayer AG, Cipla Ltd, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Dr. Reddys Laboratories Ltd, Eli Lilly and Company, Endo International PLC, Ferring Pharmaceuticals, Futura Medical PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc, Meda Pharmaceuticals, Inc., Metuchen Pharmaceuticals LLC, Mylan N.V., Novartis International AG, Pfizer, Inc., Promedon HQ, S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, and Vivus, Inc..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Erectile Dysfunction Drugs Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Erectile Dysfunction Drugs Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Erectile Dysfunction Drugs Market?
  • 4. What is the competitive strategic window for opportunities in the Global Erectile Dysfunction Drugs Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Erectile Dysfunction Drugs Market?
  • 6. What is the market share of the leading vendors in the Global Erectile Dysfunction Drugs Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Erectile Dysfunction Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Outlook
  • 3.4. Mode of Administration Outlook
  • 3.5. End-User Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in patient awareness and education levels
      • 5.1.1.2. Growing portion of geriatric population
      • 5.1.1.3. Rising adoption of a sedentary lifestyle and incidence of lifestyle diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the erectile dysfunction drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Government reforms and public awareness initiatives in developing nations
      • 5.1.3.2. R&D focused on developments of effective therapies and treatments for erectile dysfunction
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of cost-effective counterfeit drugs
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Erectile Dysfunction Drugs Market, by Drug

  • 6.1. Introduction
  • 6.2. Avanafil (Stendra)
  • 6.3. Muse Suppository (Alprostadil)
  • 6.4. Sildenafil (Viagra)
  • 6.5. Tadalafil (Cialis)
  • 6.6. Vardenafil (Levitra, Staxyn)

7. Erectile Dysfunction Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injections
  • 7.3. Oral
  • 7.4. Topical

8. Erectile Dysfunction Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Erectile Dysfunction Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Erectile Dysfunction Drugs Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Erectile Dysfunction Drugs Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Apricus Biosciences Inc.
  • 13.2. Aurobindo Pharma Ltd
  • 13.3. Bayer AG
  • 13.4. Cipla Ltd
  • 13.5. Cristalia Produtos Quimicos Farmaceuticos Ltd.
  • 13.6. Dong-A Pharmaceutical Co. Ltd.
  • 13.7. Dr. Reddys Laboratories Ltd
  • 13.8. Eli Lilly and Company
  • 13.9. Endo International PLC
  • 13.10. Ferring Pharmaceuticals
  • 13.11. Futura Medical PLC
  • 13.12. GlaxoSmithKline PLC
  • 13.13. Johnson & Johnson Services, Inc
  • 13.14. Meda Pharmaceuticals, Inc.
  • 13.15. Metuchen Pharmaceuticals LLC
  • 13.16. Mylan N.V.
  • 13.17. Novartis International AG
  • 13.18. Pfizer, Inc.
  • 13.19. Promedon HQ
  • 13.20. S.K. Chemicals Co. Ltd.
  • 13.21. Teva Pharmaceutical Industries Ltd
  • 13.22. Torrent Pharmaceuticals Ltd
  • 13.23. Vivus, Inc.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details